The C-reactive protein +1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia

Clinical Chemistry

Volumn 52, Issue 10, 2006, Pages 1952-1957

  Marsik, Claudia ^a   Sunder Plassmann, Raute ^a   Jilma, Bernd ^a,b,c   Kovar, Florian M ^a   Mannhalter, Christine ^a   Wagner, Oswald ^a   Rumpold, Helmut ^a   Endler, Georg ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Prince Court Medical Center ^*  (Austria)

^c University of Gainesville   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; D DIMER; DNA; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 6; PROTHROMBIN; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BASE MISPAIRING; BLOOD CLOTTING; BODY TEMPERATURE; CONTROLLED STUDY; ENDOTOXEMIA; GENOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; INFLAMMATION; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION;

ADULT; BLOOD COAGULATION; C-REACTIVE PROTEIN; ENDOTOXEMIA; ESCHERICHIA COLI; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MUTATION; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; PROTHROMBIN; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 33749139712     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.069823     Document Type: Article

References (45)

1. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003;96:793-807.
2. Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005;46:239-45.
3. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005;112:25-31.
4. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
5. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004;30:261-77.
6. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279:48487-90.
7. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004;116(Suppl 6A):9S-16S.
8. Yen ML, Yang CY, Yen BL, Ho YL, Cheng WC, Bai CH. Increased high sensitivity C-reactive protein and neutrophil count are related to increased standard cardiovascular risk factors in healthy Chinese men. Int J Cardiol 2006;110:191-8.
9. Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr 2004;80:862-7.
10. Melamed S, Shirom A, Toker S, Berliner S, Shapira I. Association of fear of terror with low-grade inflammation among apparently healthy employed adults. Psychosom Med 2004;66:484-91.
11. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003;73:1245-52.
12. Jilma B, Dirnberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG, et al. Menstrual cycle-associated changes in blood levels of interleukin 6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 1997;130:69-75.
13. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:2063-9.
14. D'Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS. C-reactive protein (+1444C/T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005;179:413-7.
15. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005;178:139-45.
16. Hollenstein U, Homoncik M, Stohlawetz PJ, Marsik C, Sieder A, Eichler HG, et al. Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis 2000;182:343-6.
17. Jilma-Stohlawetz P, Folman CC, von dem Borne AE, Pernerstorfer T, Hollenstein U, Knechtelsdorfer M, et al. Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med 2001;137:64-9.
18. Fiuza C, Suffredini AF. Human models of innate immunity: local and systemic inflammatory responses. J Endotoxin Res 2001;7:385-8.
19. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology 1993;187:403-16.
20. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli 0:113 endotoxin. J Infect Dis 1999;179:1278-82.
21. Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 2004;32:1136-40.
22. Derhaschnig U, Pachinger C, Schweeger-Exeli I, Marsik C, Jilma B. Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. Thromb Haemost 2003;90:1054-60.
23. Marsik C, Mayr F, Cardona F, Derhaschnig U, Wagner OF, Jilma B. Endotoxaemia modulates Toll-like receptors on leucocytes in humans. Br J Haematol 2003;121:653-6.
24. Reiter R, Derhaschnig U, Spiel A, Keen P, Cardona F, Mayr F, et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003;90:898-903.
25. Jilma B, Marsik C, Mayr F, Graninger MT, Taylor FB Jr., Ribel MC, et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002;72:403-10.
26. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003;31:1108-12.
27. Haring D, Endler G, Hsieh K, Mannhalter C. Comparison of methods for determination of interleukin 6 G(-174)C promoter polymorphism. Biotechniques 2002;33:1114-7.
28. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993;21:3623-9.
29. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109 (21 Suppl 1):II2-10.
30. Westerberg M, Bengtsson A, Ricksten A, Jeppsson A. Tumor necrosis factor gene polymorphisms and inflammatory response in coronary artery bypass grafting patients. Scand Cardiovasc J 2004;38:312-7.
31. Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin 1 gene cluster and interleukin 6 gene in patients with coronary heart disease. Eur J Immunogenet 2004;31:207-13.
32. Eklund C, Lehtimaki T, Hurme M. Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin 1B SNP +3954 on CRP concentration in healthy male blood donors. Int J Immunogenet 2005;32:229-32.
33. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
34. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-45.
35. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997;89:3727-34.
36. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, Tropea M, Reda D, Agosti JM, et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998;80:114-8.
37. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004;62:499-506.
38. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect? J Am Coll Cardiol 2005;46:1496-502.
39. Agrawal A. CRP after 2004. Mol Immunol 2005;42:927-30.
40. Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, Suriyaphol P, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004;109:1870-6.
41. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
42. Kunes P. [C-reactive protein in the pathogenesis of atherosclerosis: advantage and pitfalls of the "Mainz hypothesis"]. Cas Lek Cesk 2005;144:25-31.
43. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002;162:217-9.
44. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73-9.
45. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005;69:623-38.